OBX · Obsidian Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
No transactions found.
Transaction History
No transactions found.
No transactions found.
No transactions found.
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
OBX to Present Updated Data on Advanced Melanoma Trials
Obsidian Therapeutics announced that it will present new data from its Phase 1 study and the Phase 1/2 Agni‑01 multicenter trial of amsokigene autoleucel in patients whose advanced melanoma is resistant to immune‑checkpoint inhibitors. The update focuses on safety and early efficacy signals in this difficult‑to‑treat population. The presentation may provide further insight into the company's immunotherapy pipeline.
OBX to Present Updated Data on Advanced Melanoma Trials. Obsidian Therapeutics announced that it will present new data from its Phase 1 study and the Phase 1/2 Agni‑01 multicenter trial of amsokigene autoleucel in patients whose advanced melanoma is resistant to immune‑checkpoint inhibitors. The update focuses on safety and early efficacy signals in this difficult‑to‑treat population. The presentation may provide further insight into the company's immunotherapy pipeline.